Membranous nephropathy requires risk stratification by physicians according to various indicators. For low-risk and intermediate-risk patients, i.e., patients with low urine protein amount, normal renal function, no limb swelling or mild swelling, and no complications can be treated conservatively, generally using Prilosec or Satan drugs for oral observation. For high-risk patients, i.e. with high urine protein amount, abnormal renal function, severe swelling of limbs, or even pericardial effusion, pleural effusion, or peritoneal effusion, immediate and aggressive treatment with hormones combined with immunosuppressive drugs is required. Membranous nephropathy usually does not work with hormone therapy alone, and often requires hormone therapy combined with cyclophosphamide or hormone therapy combined with cyclosporine, or hormone therapy combined with FK506 or rituximab. Treatment will also be based on comorbidities, such as diuretic therapy for patients with edema, lipid-lowering therapy for patients with hyperlipidemia, antihypertensive therapy for patients with hypertension, and anticoagulation therapy for patients with thrombosis. In conclusion, membranous nephropathy is a disease with insidious onset and slow progression. There is no nerve distribution in the kidney, so the vast majority of nephropathy deteriorates silently and painlessly, but it does not mean that the kidney is normal. Therefore, if physical examination reveals urine protein, high blood pressure and elevated blood creatinine, you should seek help from a nephrologist immediately.